SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Parsons James T. (Last) (First) (Middle) C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE (Street) MISSISSAUGA A6 L5L 1J9 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Trillium Therapeutics Inc. [ TRIL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 11/17/2021
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.03	11/17/2021		D			180,000	(1)	12/23/2030	Common Shares	180,000	$0	0	D
Stock Option (Right to Buy)	$0.3(2)	11/17/2021		D			94,792	(1)	11/07/2029	Common Shares	94,792	$0	0	D
Stock Option (Right to Buy)	$3.34(3)	11/17/2021		D			59,896	(1)	11/08/2028	Common Shares	59,896	$0	0	D
Stock Option (Right to Buy)	$7.27(4)	11/17/2021		D			5,761	(1)	11/09/2026	Common Shares	5,761	$0	0	D
Stock Option (Right to Buy)	$8.18(5)	11/17/2021		D			36,204	(1)	04/17/2024	Common Shares	36,204	$0	0	D
Stock Option (Right to Buy)	$9.65(6)	11/17/2021		D			24,390	(1)	11/09/2027	Common Shares	24,390	$0	0	D
Stock Option (Right to Buy)	$11.04(7)	11/17/2021		D			30,171	(1)	05/27/2026	Common Shares	30,171	$0	0	D
Stock Option (Right to Buy)	$15.27(8)	11/17/2021		D			30,171	(1)	11/19/2025	Common Shares	30,171	$0	0	D

Explanation of Responses:

1. On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.

2. The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

3. The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

4. The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

5. The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

6. The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

7. The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

8. The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD.

	/s/ James Parsons, Attorney-in-Fact	11/19/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.